Surabotsophon, M., Klai‐On, Y., Thanachartwet, V., Khunapornphairote, S., Chamnanchanunt, S., Racharak, T., . . . Desakorn, V. (2020). Tocilizumab for treating severe COVID‐19 pneumonia refractory to combined hydroxychloroquine, lopinavir plus ritonavir, and favipiravir: A case series. Clin Case Rep.
Chicago Stili AlıntıSurabotsophon, Manoon, et al. "Tocilizumab for Treating Severe COVID‐19 Pneumonia Refractory to Combined Hydroxychloroquine, Lopinavir Plus Ritonavir, and Favipiravir: A Case Series." Clin Case Rep 2020.
MLA AlıntıSurabotsophon, Manoon, et al. "Tocilizumab for Treating Severe COVID‐19 Pneumonia Refractory to Combined Hydroxychloroquine, Lopinavir Plus Ritonavir, and Favipiravir: A Case Series." Clin Case Rep 2020.
Uyarı: Bu alıntı herzaman %100 doğru olmayabilir..